Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
NRG Oncology/RTOG 9601, a phase III trial in...
Conference

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

Abstract

3 Background: Previous reports suggested that AAT when combined with salvage RT following RP in patients may improve prostate cancer control outcomes. Methods: Post-RP patients with pT3pN0 or with pT2pN0 and positive margins who had or developed elevated PSA levels from 0.2 to 4.0 ng/ml were randomized on a phase III, double-blind, trial of RT + placebo (64.8 Gy in 36 fractions of 1.8 Gy) vs. RT + AAT (24 months bicalutamide, …

Authors

Shipley WU; Pugh SL; Lukka HR; Major P; Heney NM; Grignon DA; Sartor O; Patel M; Bahary J-P; Zietman AL

Volume

34

Pagination

pp. 3-3

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

January 10, 2016

DOI

10.1200/jco.2016.34.2_suppl.3

Conference proceedings

Journal of Clinical Oncology

Issue

2_suppl

ISSN

0732-183X